These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2659570)

  • 21. Pharmacokinetics and metabolism of FCE 22101 following its administration as the oral pro-drug FCE 22891.
    Lovering AM; MacGowan AP; Lewis DA; Reeves DS
    J Antimicrob Chemother; 1992 Feb; 29(2):179-85. PubMed ID: 1506334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vitro interactions of FCE 22101 with aminoglycosides against gram-negative rods.
    Said AA; Livermore DM
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():103-8. PubMed ID: 2732132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo antibacterial activities of sanfetrinem cilexetil, a new oral tricyclic antibiotic.
    Tamura S; Miyazaki S; Tateda K; Ohno A; Ishii Y; Matsumoto T; Furuya N; Yamaguchi K
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1858-61. PubMed ID: 9661036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bactericidal activity of teicoplanin in an in-vitro two-compartment kinetic model.
    Pallanza R; Scotti R; Arioli V
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():15-21. PubMed ID: 2965127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and in vivo evaluation of the penem FCE 22101 and its orally absorbed ester FCE 22891.
    Bruna CD; Jabes D; Sebben G; Sanfilippo A
    G Ital Chemioter; 1983; 30(2-3):125-30. PubMed ID: 6329870
    [No Abstract]   [Full Text] [Related]  

  • 26. The in-vitro activity of a novel penem FCE 22101 compared to other beta-lactam antibiotics.
    Neu HC; Chin NX; Labthavikul P
    J Antimicrob Chemother; 1985 Sep; 16(3):305-13. PubMed ID: 2997100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-vitro activity of two new carbapenems FCE 22101 and CGP 31608 in comparison with imipenem.
    Van der Auwera P; Ernst F; Grenier P; Glupczynski Y; Husson M; Klastersky J
    J Antimicrob Chemother; 1987 Aug; 20(2):179-89. PubMed ID: 3478328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An in vitro model for the study of antibacterial dosage regimen design.
    Toothaker RD; Welling PG; Craig WA
    J Pharm Sci; 1982 Aug; 71(8):861-4. PubMed ID: 7120086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
    Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
    Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-vitro activity of pefloxacin compared to other antibiotics.
    Yourassowsky E; Van der Linden MP; Crokaert F; Glupczynski Y
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():19-28. PubMed ID: 3086279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review of the in-vitro evaluation of FCE 22101.
    Wise R; Ballard RC
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():7-16. PubMed ID: 2659572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [In vitro antibacterial activity of a new parenteral penem, sulopenem].
    Yoshida T; Tateda E; Hiramatsu K; Yokota T
    Jpn J Antibiot; 1996 Apr; 49(4):324-37. PubMed ID: 8786624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of penems against methicillin-resistant Staphylococcus aureus.
    Holt HA; Bywater MJ; Reeves DS
    J Antimicrob Chemother; 1988 Jul; 22(1):87-8. PubMed ID: 3170396
    [No Abstract]   [Full Text] [Related]  

  • 35. Low antibiotic resistance rates in Staphylococcus aureus, Escherichia coli and Klebsiella spp but not in Enterobacter spp and Pseudomonas aeruginosa: a prospective observational study in 14 Swedish ICUs over a 5-year period.
    Hanberger H; Burman LG; Cars O; Erlandsson M; Gill H; Nilsson LE; Nordlinder D; Walther SM;
    Acta Anaesthesiol Scand; 2007 Aug; 51(7):937-41. PubMed ID: 17635399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Searching for a potential antibacterial lead structure against bacterial biofilms among new naphthoquinone compounds.
    Moreira CS; Silva AC; Novais JS; Sá Figueiredo AM; Ferreira VF; da Rocha DR; Castro HC
    J Appl Microbiol; 2017 Mar; 122(3):651-662. PubMed ID: 27930849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem.
    Ueda Y; Kanazawa K; Eguchi K; Takemoto K; Eriguchi Y; Sunagawa M
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4185-96. PubMed ID: 16189097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and antimicrobial spectrum of FCE 22101 and its orally available ester FCE 22891.
    Franceschi G; Perrone E; Alpegiani M; Bedeschi A; Battistini C; Zarini F; Della Bruna C
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():1-6. PubMed ID: 2659569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of FCE 22101-resistant Enterobacteriaceae and the effect of FCE 22101 upon the activity of anti-pseudomonal beta-lactams for Pseudomonas aeruginosa.
    Piddock LJ; Traynor EA
    J Antimicrob Chemother; 1991 Sep; 28(3):369-75. PubMed ID: 1960118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of [14C]FCE 22891, a penem antibiotic, following oral administration to healthy volunteers.
    Efthymiopoulos C; Strolin Benedetti M; Sassella D; Boobis A; Davies D
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1958-63. PubMed ID: 1416887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.